Essex Investment Management Co. LLC Has $326,000 Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Essex Investment Management Co. LLC lowered its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 10.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,442 shares of the company’s stock after selling 2,810 shares during the quarter. Essex Investment Management Co. LLC owned about 0.09% of Eton Pharmaceuticals worth $326,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Wasatch Advisors LP acquired a new stake in Eton Pharmaceuticals in the 3rd quarter worth about $1,431,000. Baader Bank Aktiengesellschaft bought a new position in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $373,000. Jane Street Group LLC bought a new position in shares of Eton Pharmaceuticals during the third quarter worth approximately $90,000. Geode Capital Management LLC raised its position in shares of Eton Pharmaceuticals by 13.5% in the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after buying an additional 32,365 shares in the last quarter. Finally, Anchor Capital Advisors LLC bought a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $805,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Price Performance

Shares of ETON opened at $14.59 on Monday. The firm has a 50 day simple moving average of $15.22 and a two-hundred day simple moving average of $10.92. Eton Pharmaceuticals, Inc. has a one year low of $3.03 and a one year high of $18.41. The company has a market cap of $380.08 million, a P/E ratio of -66.32 and a beta of 1.37.

Wall Street Analysts Forecast Growth

ETON has been the topic of a number of recent research reports. Craig Hallum raised their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. B. Riley started coverage on Eton Pharmaceuticals in a research report on Friday, January 10th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.